Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2010 Oct 5:2011:563216.
doi: 10.4061/2011/563216.

Immunophenotypical Switch versus Tumor Heterogeneity in a Patient with HIV-Associated Diffuse Large B-Cell Lymphoma

Jorge J Castillo  1 , Tina Rizack, Diana Treaba
Affiliations
Case Reports

Immunophenotypical Switch versus Tumor Heterogeneity in a Patient with HIV-Associated Diffuse Large B-Cell Lymphoma

Jorge J Castillo et al. Patholog Res Int. .

Abstract

Patients with HIV/AIDS have a higher risk of developing aggressive B-cell lymphomas, such as diffuse large B-cell lymphoma (DLBCL). Lymphomas are rather heterogeneous in nature and in a few cases can switch their genetic or immunohistochemical phenotype, transform into other lymphomas or carry more than one malignant clone. In this report, we present the case of a 47-year-old man with HIV infection who was diagnosed with an apparent low-risk, early-stage DLBCL, but became refractory to therapy while undergoing treatment with rituximab-containing chemotherapy. We postulate that the development of his refractory disease occurred in the context of an immunohistochemical switch or the surge of a clone refractory to therapy. This phenomenon was not associated with a superinfection with EBV or HHV-8.

PubMed Disclaimer

Figures

Figure 1
Figure 1
CD20-positive diffuse large B-cell lymphoma with a germinal center immunophenotypical profile (initial excisional biopsy).
Figure 2
Figure 2
CD20-negative diffuse large B-cell lymphoma with a nongerminal center immunophenotypical profile (second excisional biopsy).
See this image and copyright information in PMC

References

    1. Stein H, Warnke R, Chan W, et al. Diffuse large B-cell lymphoma, not otherwise specified. In: Swerdlow S, Campo E, Harris N, et al., editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC; 2008. pp. 233–237.
    1. Kirk O, Pedersen C, Cozzi-Lepri A, et al. Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood. 2001;98(12):3406–3412. - PubMed
    1. Polesel J, Franceschi S, Suligoi B, et al. Cancer incidence in people with AIDS in Italy. International Journal of Cancer. 2010;127(6):1437–1445. - PubMed
    1. Feugier P, van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the groupe d’Etude des Lymphomes de l’Adulte. Journal of Clinical Oncology. 2005;23(18):4117–4126. - PubMed
    1. Pfreundschuh M, Trümper L, Österborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncology. 2006;7(5):379–391. - PubMed

Publication types

LinkOut - more resources